HGF and NRG1 protein expression are not poor prognostic markers in surgically resected lung adenocarcinoma

OncoTargets and Therapy

Volumn 8, Issue , 2015, Pages 1185-1191

  Pan, Bin ^a,b   Wang, Rui ^a,b   Huang, Yangle ^a,b   Garfield, David ^c   Zhang, Jie ^a,b   Chen, Haiquan ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

HGF; NRG1; Prognosis; Resected lung adenocarcinoma

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NEU DIFFERENTIATION FACTOR; SCATTER FACTOR; VASCULOTROPIN RECEPTOR;

ADULT; AGED; ALK GENE; ARTICLE; BRAF GENE; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; DISEASE ASSOCIATION; EGFR GENE; FEMALE; GENE FUSION; GENE MUTATION; HER2 GENE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KRAS GENE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; ONCOGENE; OVERALL SURVIVAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; TISSUE DIFFERENTIATION;

EID: 84930617513     PISSN: 11786930     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S78116     Document Type: Article

References (17)

1. Jemal A, Bray F, Center MM, et al., Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
2. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3(75):75ra26.
3. Garrett JT, Arteaga CL. Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications. Cancer Biol Ther. 2011;11(9):793–800.
4. Straussman R, Morikawa T, Shee K, et al. Tumor microenvironment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012;487(7408):500–504.
5. Wilson TR, Fridlyand J, Yan Y, et al. Widespread potential for growthfactor-driven resistance to anticancer kinase inhibitors. Nature. 2012; 487(7408):505–509.
6. Masuya D, Huang C, Liu D, et al. The tumour–stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non–small cell lung cancer patients. Br J Cancer. 2004;90(8):1555–1562.
7. Cappuzzo F, Marchetti A, Skokan M, et al. Increased MET gene copy number negatively affects survival of surgically resected non–small cell lung cancer patients. J Clin Oncol. 2009;27(10):1667–1674.
8. Beau-Faller M, Ruppert A, Voegeli A, et al. MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naive cohort. J Thorac Oncol. 2008;3(4):331–339.
9. Siegfried JM, Weissfeld LA, Luketich JD, et al. The clinical significance of hepatocyte growth factor for non–small cell lung cancer. Ann Thorac Surg. 1998;66(6):1915–1918.
10. Huang HE, Chin SF, Ginestier C, et al. A recurrent chromosome breakpoint in breast cancer at the NRG1/neuregulin1/heregulin gene. Cancer Res. 2004;64(19):6840–6844.
11. Lin MC, Rojas KS, Cerione RA, Wilson KF. Identification of mTORC2 as a necessary component of HRG/ErbB2-dependent cellular transformation. Mol Cancer Res. 2014;12(6):940–952.
12. Hegde GV, de la Cruz CC, Chiu C, et al. Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung. Sci Transl Med. 2013;5(171):171ra18.
13. Hartmut Koeppen, Wei Yu, Jiping Zha, et al. Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib±Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit. Clin Cancer Res. 2014;20(17): 4488–4498.
14. Wang R, Pan Y, Li C, et al. The use of quantitative real-time reverse transcriptase PCR for 50 and 30 portions of ALK transcripts to detect ALK rearrangements in lung cancers. Clin Cancer Res. 2012;18(17): 4725–4732.
15. Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest. 2009;136(1):260–271.
16. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6(2):244–285.
17. Israel Cañadas, Álvaro Taus, Iria González, et al. High circulating hepatocyte growth factor levels associate with epithelial to mesenchymal transition and poor outcome in small cell lung cancer patients. Oncotarget. 2014;5(14):5246–5256.